Sheehan's syndrome epidemiology and demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]
Overview
Overview
The incidence of Sheehan’s syndrome is difficult to assess. It was found to be the 6th most common cause of growth hormone (GH) deficiency with an incidence of 3.1% of cases. In 2009, the prevalence of Sheehan’s syndrome was estimated to be 5.1 per 100,000 women. It is less prevalent in developed countries due to better obstetrical care and maternal health awareness. It is still one of the most common causes of hypopituitarism in developing countries.
Epidemiology and Demographics
Epidemiology and Demographics
Incidence
- The incidence of Sheehan’s syndrome is difficult to assess.[1]
- It was found to be the 6th most common cause of GH deficiency with an incidence of 3,100 per 100,000 persons.[2]
- Nowadays, Sheehan’s syndrome is not a common consequence of puerperal hemorrhage due to improved obstetrical care.[3]
Prevalence
- In 2009, the prevalence of Sheehan’s syndrome was estimated to be 5.1 per 100,000 women in Iceland.[4]
Age
- Sheehan’s syndrome is usually diagnosed in women of childbearing age only.
Race
- There is no racial predilection for Sheehan’s syndrome but it usually affects females of Asian or Hispanic ethnicity.
Gender
- Sheehan’s syndrome affects only females.
Region
- The majority of Sheehan’s syndrome cases are reported in developing countries.
Developed Countries
- It is less prevalent in developed countries due to better obstetrical care and maternal health awareness.[3][5]
Developing Countries
- It is still one of the most common causes of hypopituitarism in developing countries.[5]
References
References
- ↑ Asaoka K (1977). “[A study on the incidence of post-partum hypopituitarism, (Sheehan’s syndrome)]”. Nihon Naibunpi Gakkai Zasshi (in Japanese). 53 (7): 895–909. PMID 303183.
- ↑ Abs R, Bengtsson BA, Hernberg-Stâhl E, Monson JP, Tauber JP, Wilton P, Wüster C (1999). “GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety”. Clin. Endocrinol. (Oxf). 50 (6): 703–13. PMID 10468941.
- ↑ 3.0 3.1 Feinberg EC, Molitch ME, Endres LK, Peaceman AM (2005). “The incidence of Sheehan’s syndrome after obstetric hemorrhage”. Fertil. Steril. 84 (4): 975–9. doi:10.1016/j.fertnstert.2005.04.034. PMID 16213852.
- ↑ Kristjansdottir HL, Bodvarsdottir SP, Sigurjonsdottir HA (2011). “Sheehan’s syndrome in modern times: a nationwide retrospective study in Iceland”. Eur. J. Endocrinol. 164 (3): 349–54. doi:10.1530/EJE-10-1004. PMID 21183555.
- ↑ 5.0 5.1 Krysiak R, Okopień B (2015). “[Sheehan’s syndrome–a forgotten disease with 100 years’ history]”. Prz. Lek. (in Polish). 72 (6): 313–20. PMID 26817341.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
